| Melissa A. Kelly Behrs |
Melissa A. Kelly Behrs is currently the Chief Alliance Officer & EVP-Business Operations at Geron Corp. She previously worked at Genetics Institute LLC as the Associate Director-Preclinical Operations. Ms. Behrs holds an MBA from Babson College and an undergraduate degree from Boston College. |
| Michelle Robertson |
Michelle Robertson is currently an Independent Director at Verastem, Inc. and will be the Chief Financial Officer, Treasurer & Executive VP at Geron Corp. starting in 2023. She was previously the Treasurer, Chief Financial & Accounting Officer at Momenta Pharmaceuticals, Inc. from 2017 to 2020, Head-Financial Planning & Analysis at Ironwood Pharmaceuticals, Inc. from 2012 to 2015, Vice President-Oncology Finance at Baxalta, Inc. in 2015-2016, and the Chief Financial Officer, Treasurer & Executive VP at Editas Medicine, Inc. from 2020 to 2023. Ms. Robertson received her undergraduate degree from Bentley University. |
| Edward E. Koval |
Edward E. Koval is currently the Chief Business Officer & Executive Vice President at Geron Corp. He previously worked as the Senior Vice President-Corporate Development at X-Chem, Inc. from 2013 to 2020 and as the Vice President-Business & Strategic Corporate Development at Veloxis Pharmaceuticals A from 2010 to 2012. He also served as the Chief Business Officer at Zebiai Therapeutics, Inc. Mr. Koval received his undergraduate degree from New York University, his graduate degree from Rensselaer Polytechnic Institute, and his MBA from MIT Sloan School of Management. |
| Anil Kapur |
Anil Kapur is an Independent Director at Verastem, Inc. and the Chief Commercial Officer & EVP-Corporate Strategy at Geron Corp. He previously worked as VP, Head-Early Assets & Biomarkers at Bristol Myers Squibb Co., VP & Commercial Leader-Hematology Franchise at Johnson & Johnson, VP, Global Head-Commercial & Portfolio Strategy at Baxalta, Inc., and Chief Commercial Officer at Actinium Pharmaceuticals, Inc. He also served as Head-Legal at Sagar Ratna Restaurants Pvt Ltd. and Legal Advisor at Paras Group. Mr. Kapur holds undergraduate and graduate degrees from Birla Institute of Technology & Science and Kurukshetra University, respectively, and an MBA from The Fuqua School of Business at Duke University. |
| Faye Feller |
Faye Feller is currently working as the Chief Medical Officer & Executive Vice President at Geron Corp. Prior to this, Dr. Feller worked as a Senior Director at Janssen Research & Development LLC. Dr. Feller completed their undergraduate degree at New York University and holds a doctorate from Icahn School of Medicine at Mount Sinai. |
| John A. Scarlett |
John A. Scarlett was the founder of Sensus Drug Development Corp. (founded in 1993) where he served as President & Chief Executive Officer from 1993 to 2001. He was also the founder of Tercica, Inc. (founded in 2002) where he held the position of Chief Executive Officer & Director from 2007 to 2008. Additionally, Dr. Scarlett founded Covance Biotechnology Services, Inc. (founded in 1995) and served as a Director from 1995 to 2000. Dr. Scarlett is also the founder of Labcorp Drug Development, Inc. Dr. Scarlett's current job is Chairman, President & Chief Executive Officer at Geron Corp. since 2011. Among his former positions, he was President & Chief Executive Officer at Proteolix, Inc. in 2009, Independent Director at Chiasma, Inc. from 2015 to 2021, Director-Medical Research & Services at Ortho-McNeil Pharmaceutical LLC from 1982 to 1985, Independent Director at CytomX Therapeutics, Inc. from 2016 to 2022, Vice President-Clinical Affairs at Greenwich Pharmaceuticals, Inc. from 1985 to 1990, and Senior Vice President-Medical & Scientific Affairs at Novo Nordisk Pharmaceutical Industries, Inc. from 1991 to 1993. Dr. Scarlett's education includes an undergraduate degree from Earlham College and a doctorate degree from Pritzker School of Medicine. |
| Andrew J. Grethlein |
Andrew J. Grethlein is currently the Chief Operating Officer & Executive Vice President at Geron Corp. He previously worked as the Senior Director-South San Francisco Pharmaceutical at Elan Corp. Plc from 1997 to 2003, Manager-Biologics Development & Manufacturing at Athena Neurosciences LLC from 1995 to 1997, Senior Vice President-Pharmaceutical Operations at Tercica, Inc. from 2003 to 2008, Senior Vice President-Hematology at Ipsen SA from 2008 to 2010, and Chief Operating Officer & Executive Vice President at Inspiration Biopharmaceuticals, Inc. from 2010 to 2012. He also held a position as Principal at Ipsen International GmbH. Dr. Grethlein holds a graduate and doctorate degree from Michigan State University, an undergraduate degree from Bates College, and an undergraduate degree from Bard College at Simon's Rock. |
| Susan M. Molineaux |
Susan M. Molineaux was the founder of Proteolix, Inc. (founded in 2003) and Calithera Biosciences, Inc. (founded in 2010), where she holds the title of Chief Scientific Officer and President, Chief Executive Officer & Director respectively. She currently holds the position of Independent Director at Geron Corp. (since 2012), Repare Therapeutics, Inc. (since 2023), and Smith College (since 2017). She is also a Scientific Advisor at LSV Capital Management LLC. In her former roles, she served as Co-Vice Chairman at The Bay Area Bioscience Association, Independent Director at Theravance Biopharma, Inc. (from 2015 to 2022), Secretary & Director at We Teach Science Foundation, Director at California Biomedical Innovation Alliance, Independent Director at Cyteir Therapeutics, Inc. (from 2020 to 2023), Director at California Life Sciences Association, Scientist-Immunology Group at Merck & Co., Inc. (from 1989 to 1994), Vice President-Drug Development at Praecis Pharmaceuticals, Inc. (from 1994 to 1999), Vice President-Biology at Rigel Pharmaceuticals, Inc. (from 2000 to 2003), and Vice President-Biology at Praelux, Inc. (from 1999 to 2000). She obtained her undergraduate degree from Smith College and her doctorate degree from The Johns Hopkins University. |
| Dawn Carter Bir |
Dawn Carter Bir is an Independent Director at Geron Corp. She previously held positions as Vice President-Sales at Pharmacyclics LLC from 2013 to 2016, Chief Commercial Officer & Vice President at Reata Pharmaceuticals, Inc. from 2016 to 2023, Vice President-Sales & Marketing at Sky Pharmaceuticals Packaging, Inc. from 2011 to 2013, Vice President-Sales & Marketing at McKesson Pharmaceutical from 2013 to 2016, and Vice President-Sales & Marketing at McKesson Rxpak, Inc. from 2011 to 2013. She is also a Member of Bristol-Myers Squibb Co. Ms. Bir obtained her undergraduate degree from the State University of New York at Binghamton. |
| Elizabeth G. O'Farrell |
Elizabeth G. O'Farrell is currently serving as the Chairman at PDL BioPharma, Inc. since 2020, as an Independent Director at Geron Corp. since 2019, as an Independent Director at LENSAR, Inc. since 2021, as an Independent Director at Genmab A since 2022, and as a Director at Karius, Inc. since 2023. In the past, Ms. O'Farrell held positions such as Chairman at Y.M.C.A. Foundation of Greater Indianapolis from 2014 to 2016, Chief Financial Officer & Executive Director at Eli Lilly Canada, Inc., Director at Washington Township Schools Foundation from 2003 to 2010, Independent Director at Inhibikase Therapeutics, Inc. from 2019 to 2022, Director at Keep Indianapolis Beautiful, Inc., Chief Procurement Officer at Eli Lilly & Co. from 2012 to 2017, Accountant at OfficeMax Contract, Inc., Auditor at Pricewaterhouse LLP, Auditor at Whipple & Co., and Manager at Somerset Financial Services LLC. Ms. O'Farrell also served as the Chief Financial Office and SVP-Policy & Finance at Lilly USA LLC. Ms. O'Farrell completed an MBA from Indiana University in 1987 and an undergraduate degree from Indiana University in 1986. |
| V. Bryan Lawlis |
V. Bryan Lawlis is the founder of Itero Biopharmaceuticals, Inc. (founded in 2007), Covance Biotechnology Services, Inc. (founded in 1996), and Itero Biopharmaceuticals LLC (founded in 2011). He held the titles of President & Chief Executive Officer at Itero Biopharmaceuticals, Inc. from 2007 to 2011, Chairman at Covance Biotechnology Services, Inc. from 1999 to 2001, and President & Chief Executive Officer at Itero Biopharmaceuticals LLC from 2011 to 2017. His current jobs include being an Independent Director at Geron Corp. since 2012, a Director at ReForm Biologics LLC, a Director at Tspan LLC since 2017, and a Director at Comera Life Sciences, Inc.His former jobs include being the Chief Executive Officer & Director at Aradigm Corp. from 2005 to 2006, President & Chief Executive Officer at Itero Holdings LLC from 2011 to 2017, Director at Humanigen, Inc. from 2013 to 2014, Independent Director at Sutro Biopharma, Inc. from 2003 to 2019, Independent Director at Spyre Therapeutics, Inc. from 2018 to 2023, Director at GlycoFi, Inc., Independent Director at Coherus BioSciences, Inc. from 2014 to 2021, Independent Director at Absci Corp., Director at Comera Life Sciences Holdings, Inc., and Independent Non-Executive Director at BioMarin Pharmaceutical, Inc. from 2014 to 2024. He also held the position of Vice President-Process Sciences at Genentech, Inc. from 1981 to 1996 and Senior Scientist at Genencor International, Inc. in 1996. Dr. Lawlis obtained an undergraduate degree from The University of Texas at Austin and a doctorate degree from Washington State University in 1979. |
| Robert Jay Spiegel |
Robert Jay Spiegel is the founder of Spiegel Consultants, LLC, which was founded in 2010. He is currently the Vice Chairman at Cyclacel Pharmaceuticals, Inc., an Independent Director at Geron Corp., Athenex, Inc., RenovoRx, Inc., Sun Pharma Advanced Research Co. Ltd., and Ayala Pharmaceuticals, Inc. He is also an Advisor at Warburg Pincus & Company US LLC, an Associate Professor at Weill Cornell Medical College, and a Venture Advisor at Israel Biotech Fund. Dr. Spiegel has held former positions as Chairman at NexImmune, Inc., Independent Director at Capstone Therapeutics Corp., Director at Avior Computing Corp., Independent Director at Edge Therapeutics, Inc., Director at Talon Therapeutics, Inc., Director at Advaxis, Inc., Independent Director at Sucampo Pharmaceuticals LLC, Director at Weifa ASA, Director at The Cancer Institute of New Jersey, Director at CancerCare of New Jersey, Director at Vidac Pharma Ltd., Director-Developmental Therapeutics at New York University Medical Center, Director at PDS Biotechnology Corp., and Independent Director at Old Ayala, Inc. He was also the Chief Medical Officer & Senior Vice President at Schering-Plough Research Institute and Senior Vice President at Worldwide Clinical Research, Inc. Dr. Spiegel holds a doctorate degree from the University of Pennsylvania and an undergraduate degree from Yale University (conferred in 1971). |
| John F. McDonald |
John F. McDonald is the founder of Solasia Pharma KK, which was founded in 2006. He currently holds positions as an Independent Director at Geron Corp. and Nouscom AG, and as a Director at Nouscom Srl. He previously held positions as a Director at CalciMedica, Inc. (US), Managing Director at MPM BioImpact, Inc., Vice President-Business Development at Millennium Pharmaceuticals, Inc., and Head-Business Development, Mergers & Acquisition at Biogen, Inc. from 2011 to 2018. He also worked as a Principal at Genzyme Corp. Mr. McDonald received a graduate degree from the University of California, Hastings and undergraduate and MBA degrees from Haas School of Business. |
| Gaurav Aggarwal |
Gaurav Aggarwal is currently serving as an Independent Director at Geron Corp., Unicycive Therapeutics, Inc., and as the Managing Partner at Vivo Capital LLC. Previously, he held positions as a Director at Vela Pharmaceuticals, Inc., Sierra Oncology, Inc., Piramed Ltd., Alvine Pharmaceuticals, Inc., Hyperion Therapeutics, Inc., NextWave Pharmaceuticals, Inc., Microlin Bio, Inc., FlowCardia, Inc., Auspex Pharmaceuticals, Inc., Patricia Industries AB, J.P. Morgan Partners LLC, OCERA Therapeutics LLC, KBL Healthcare Ventures, Panorama Capital LLC, and Wasserstein Perella & Co., Inc. Dr. Aggarwal obtained his undergraduate degree from Cornell University in 1994 and his doctorate from Columbia University College of Physicians & Surgeons in 2000. His current job(s) include Independent Director at Geron Corp., Independent Director at Unicycive Therapeutics, Inc., and Managing Partner at Vivo Capital LLC. |
